Antithrombin III injection via the portal vein suppresses liver damage

Masayuki Miyazaki, Masaki Kato, Masatake Tanaka, Kosuke Tanaka, Shinichiro Takao, Motoyuki Kohjima, Tetsuhide Ito, Munechika Enjoji, Makoto Nakamuta, Kazuhiro Kotoh, Ryoichi Takayanagi

研究成果: ジャーナルへの寄稿記事

8 引用 (Scopus)

抄録

AIM: To investigate the effects of antithrombin III (AT III) injection via the portal vein in acute liver failure. METHODS: Thirty rats were intraperitoneally challenged with lipopolysaccharide (LPS) and D-galactosamine (GalN) and divided into three groups: A control group; a group injected with AT III via the tail vein; and a group injected with AT III via the portal vein. AT III (50 U/kg body weight) was administrated 1 h after challenge with LPS and GalN. Serum levels of inflammatory cytokines and fibrin degradation products, hepatic fibrin deposition, and hepatic mRNA expression of hypoxiarelated hypoxiarelated genes were analyzed. RESULTS: Serum levels of alanine aminotransferase, tumor necrosis factor-α and interleukin-6 decreased significantly following portal vein AT III injection compared with tail vein injection, and control rats. Portal vein AT III injection reduced liver cell destruction and decreased hepatic fibrin deposition. This treatment also significantly reduced hepatic mRNA expression of lactate dehydrogenase and heme oxygenase-1. CONCLUSION: A clinically acceptable dose of AT III injection into the portal vein suppressed liver damage, probably through its enhanced anticoagulant and antiinflammatory activities.

元の言語英語
ページ(範囲)1884-1891
ページ数8
ジャーナルWorld Journal of Gastroenterology
18
発行部数16
DOI
出版物ステータス出版済み - 4 28 2012

Fingerprint

Antithrombin III
Portal Vein
Injections
Liver
Galactosamine
Fibrin
Lipopolysaccharides
Tail
Veins
Fibrin Fibrinogen Degradation Products
Messenger RNA
Heme Oxygenase-1
Acute Liver Failure
Serum
Alanine Transaminase
L-Lactate Dehydrogenase
Anticoagulants
Interleukin-6
Anti-Inflammatory Agents
Tumor Necrosis Factor-alpha

All Science Journal Classification (ASJC) codes

  • Gastroenterology

これを引用

Antithrombin III injection via the portal vein suppresses liver damage. / Miyazaki, Masayuki; Kato, Masaki; Tanaka, Masatake; Tanaka, Kosuke; Takao, Shinichiro; Kohjima, Motoyuki; Ito, Tetsuhide; Enjoji, Munechika; Nakamuta, Makoto; Kotoh, Kazuhiro; Takayanagi, Ryoichi.

:: World Journal of Gastroenterology, 巻 18, 番号 16, 28.04.2012, p. 1884-1891.

研究成果: ジャーナルへの寄稿記事

Miyazaki, M, Kato, M, Tanaka, M, Tanaka, K, Takao, S, Kohjima, M, Ito, T, Enjoji, M, Nakamuta, M, Kotoh, K & Takayanagi, R 2012, 'Antithrombin III injection via the portal vein suppresses liver damage', World Journal of Gastroenterology, 巻. 18, 番号 16, pp. 1884-1891. https://doi.org/10.3748/wjg.v18.i16.1884
Miyazaki, Masayuki ; Kato, Masaki ; Tanaka, Masatake ; Tanaka, Kosuke ; Takao, Shinichiro ; Kohjima, Motoyuki ; Ito, Tetsuhide ; Enjoji, Munechika ; Nakamuta, Makoto ; Kotoh, Kazuhiro ; Takayanagi, Ryoichi. / Antithrombin III injection via the portal vein suppresses liver damage. :: World Journal of Gastroenterology. 2012 ; 巻 18, 番号 16. pp. 1884-1891.
@article{bd4a62f8aaa943f9bd0f724479f7db99,
title = "Antithrombin III injection via the portal vein suppresses liver damage",
abstract = "AIM: To investigate the effects of antithrombin III (AT III) injection via the portal vein in acute liver failure. METHODS: Thirty rats were intraperitoneally challenged with lipopolysaccharide (LPS) and D-galactosamine (GalN) and divided into three groups: A control group; a group injected with AT III via the tail vein; and a group injected with AT III via the portal vein. AT III (50 U/kg body weight) was administrated 1 h after challenge with LPS and GalN. Serum levels of inflammatory cytokines and fibrin degradation products, hepatic fibrin deposition, and hepatic mRNA expression of hypoxiarelated hypoxiarelated genes were analyzed. RESULTS: Serum levels of alanine aminotransferase, tumor necrosis factor-α and interleukin-6 decreased significantly following portal vein AT III injection compared with tail vein injection, and control rats. Portal vein AT III injection reduced liver cell destruction and decreased hepatic fibrin deposition. This treatment also significantly reduced hepatic mRNA expression of lactate dehydrogenase and heme oxygenase-1. CONCLUSION: A clinically acceptable dose of AT III injection into the portal vein suppressed liver damage, probably through its enhanced anticoagulant and antiinflammatory activities.",
author = "Masayuki Miyazaki and Masaki Kato and Masatake Tanaka and Kosuke Tanaka and Shinichiro Takao and Motoyuki Kohjima and Tetsuhide Ito and Munechika Enjoji and Makoto Nakamuta and Kazuhiro Kotoh and Ryoichi Takayanagi",
year = "2012",
month = "4",
day = "28",
doi = "10.3748/wjg.v18.i16.1884",
language = "English",
volume = "18",
pages = "1884--1891",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "16",

}

TY - JOUR

T1 - Antithrombin III injection via the portal vein suppresses liver damage

AU - Miyazaki, Masayuki

AU - Kato, Masaki

AU - Tanaka, Masatake

AU - Tanaka, Kosuke

AU - Takao, Shinichiro

AU - Kohjima, Motoyuki

AU - Ito, Tetsuhide

AU - Enjoji, Munechika

AU - Nakamuta, Makoto

AU - Kotoh, Kazuhiro

AU - Takayanagi, Ryoichi

PY - 2012/4/28

Y1 - 2012/4/28

N2 - AIM: To investigate the effects of antithrombin III (AT III) injection via the portal vein in acute liver failure. METHODS: Thirty rats were intraperitoneally challenged with lipopolysaccharide (LPS) and D-galactosamine (GalN) and divided into three groups: A control group; a group injected with AT III via the tail vein; and a group injected with AT III via the portal vein. AT III (50 U/kg body weight) was administrated 1 h after challenge with LPS and GalN. Serum levels of inflammatory cytokines and fibrin degradation products, hepatic fibrin deposition, and hepatic mRNA expression of hypoxiarelated hypoxiarelated genes were analyzed. RESULTS: Serum levels of alanine aminotransferase, tumor necrosis factor-α and interleukin-6 decreased significantly following portal vein AT III injection compared with tail vein injection, and control rats. Portal vein AT III injection reduced liver cell destruction and decreased hepatic fibrin deposition. This treatment also significantly reduced hepatic mRNA expression of lactate dehydrogenase and heme oxygenase-1. CONCLUSION: A clinically acceptable dose of AT III injection into the portal vein suppressed liver damage, probably through its enhanced anticoagulant and antiinflammatory activities.

AB - AIM: To investigate the effects of antithrombin III (AT III) injection via the portal vein in acute liver failure. METHODS: Thirty rats were intraperitoneally challenged with lipopolysaccharide (LPS) and D-galactosamine (GalN) and divided into three groups: A control group; a group injected with AT III via the tail vein; and a group injected with AT III via the portal vein. AT III (50 U/kg body weight) was administrated 1 h after challenge with LPS and GalN. Serum levels of inflammatory cytokines and fibrin degradation products, hepatic fibrin deposition, and hepatic mRNA expression of hypoxiarelated hypoxiarelated genes were analyzed. RESULTS: Serum levels of alanine aminotransferase, tumor necrosis factor-α and interleukin-6 decreased significantly following portal vein AT III injection compared with tail vein injection, and control rats. Portal vein AT III injection reduced liver cell destruction and decreased hepatic fibrin deposition. This treatment also significantly reduced hepatic mRNA expression of lactate dehydrogenase and heme oxygenase-1. CONCLUSION: A clinically acceptable dose of AT III injection into the portal vein suppressed liver damage, probably through its enhanced anticoagulant and antiinflammatory activities.

UR - http://www.scopus.com/inward/record.url?scp=84860491081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860491081&partnerID=8YFLogxK

U2 - 10.3748/wjg.v18.i16.1884

DO - 10.3748/wjg.v18.i16.1884

M3 - Article

VL - 18

SP - 1884

EP - 1891

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 16

ER -